Xefocam: effective pain relief for injuries and diseases

Compound

1 tablet of Xefocam may contain 4 or 8 mg of the active ingredient lornoxicam and auxiliary components: povidone K25, magnesium stearate, cellulose, talc, croscarmellose sodium, lactose monohydrate, titanium dioxide, macrogol 6000 , hypromellose.
One bottle of Xefocam lyophilisate contains 8 mg of the active ingredient lornoxicam and auxiliary components: disodium edetate, trometamol, mannitol.

Release form

White oblong tablets (4 mg dosage) engraved with “LO4”.

• 10 pieces in a blister - 10, 1, 2, 3 or 5 blisters in a pack of paper.

White oblong tablets (dosage 8 mg) engraved with the inscription “LO8”.

• 10 pieces in a blister - 10, 1, 2, 3 or 5 blisters in a pack of paper.

The lyophilisate for making the solution is a dense yellow mass.

• 5 glass bottles in a paper pack.
• 5 glass bottles in a plastic tray; 1 pallet in a pack of paper.

Pharmacodynamics and pharmacokinetics

Pharmacodynamics

Anti-inflammatory non-steroidal drug. It has a pronounced analgesic and anti-inflammatory effect. Lornoxicam has a rather complex mechanism of action, which includes inhibition of prostaglandin synthesis caused by inhibition of cyclooxygenase activity. Blocking cyclooxygenase leads to suppression of peripheral pain receptors and relief of signs of inflammation.

Lornoxicam also reduces the production of oxygen radicals by leukocytes that have undergone activation. The analgesic effect of the drug is not associated with an opiate-like effect on the nervous system and is not accompanied by respiratory depression or drug dependence.

Does not affect important vital signs: respiratory rate, ECG readings, body temperature, heart rate, blood pressure, spirometry .

Pharmacokinetics of tablets

After oral administration, lornoxicam is quickly and completely absorbed from the intestine. In this case, the highest concentration in the blood occurs after an hour and a half. Eating reduces the maximum concentration by 30% and increases the half-life to 2.3 hours. The bioavailability of lornoxicam reaches 92-100%. Binding to blood proteins is 99% and does not depend on its content.

The active substance is completely transformed in the liver. The enzyme CYP2C9 is involved in the transformation . In plasma, the drug is present predominantly unchanged and, only to a small extent, in the form of a hydroxylated metabolite that does not have pharmacological activity.

The half-life is approximately 4 hours. About a third of the metabolites are excreted in the urine and the remainder in the bile.

In elderly people, as well as in patients with impaired liver and kidney function, no changes in the pharmacokinetics of the drug were detected.

Pharmacokinetics of solution for parenteral administration

When administered intramuscularly, the highest content of lornoxicam in the blood is achieved after 25 minutes. Bioavailability in this case reaches 97%, and the reaction with blood proteins is 99%.

Lornoxicam is found in plasma in unchanged form and also in the form of a hydroxylated metabolite that has no pharmacological activity.

The half-life is approximately 3.5 hours. Completely metabolized. About a third of the metabolites are excreted in the urine and the remainder in the bile.

In elderly people, as well as in patients with impaired liver and kidney function, no changes in the pharmacokinetics of the drug were detected.

Mechanism of action

Lornoxicam belongs to the category of non-opioid analgesics. In the body, it inhibits the activity of the enzyme cyclooxygenase, which is responsible for the synthesis of neurotransmitters of pain and inflammation. It also slows down oxidation reactions. The substance does not affect the thermoregulation center, breathing, the functioning of the cardiovascular system, and does not cause drug dependence.

Xefocam in tablets and solution is quickly absorbed into the blood, binding to its proteins. The analgesic effect is observed after 15–20 minutes, reaching its maximum after 1.5–2 hours. Within 3.5–4 hours, the substance is filtered by liver cells and gradually eliminated from the body through the kidneys and intestines. During its activity and elimination, the drug produces almost no metabolites.

If the instructions are followed, Xefocam does not have a pronounced toxic effect on internal organs. Its components do not accumulate in tissues. The product is approved for use by physical parameters in weakened people, with insufficient liver function and excretory system.

Indications for use

Indications for use of Xefocam in tablet form:

• short-term therapy of pain syndrome, regardless of origin;
• symptomatic treatment of rheumatic diseases: nylosing spondylitis , osteoarthritis , articular syndrome in acute gout , rheumatoid arthritis , rheumatic lesions of periarticular soft tissues.

The drug is used in the form of injections for short-term treatment of acute pain of a moderate, mild and moderately severe nature.

For what pathologies is Xefocam indicated?

Injections are prescribed intramuscularly and intravenously to eliminate the inflammatory process and acute pain:

• during attacks of lumbodynia caused by intervertebral hernias, pinched nerve endings of the spine, exacerbations of osteochondrosis, spondyloarthrosis;
• for sciatica;
• with neuralgic attacks;
• for injuries of the vertebrae and joints;
• during the recovery period after surgery;
• for chronic symptoms of rheumatism, osteoarthritis and arthritis of various origins.

Xefocam does not affect the general course of the disease, but significantly improves the physical condition, reducing acute pain and restoring the limited mobility of the musculoskeletal system.

Contraindications

• combination (complete or incomplete) of polyposis of the paranasal sinuses or nose, bronchial asthma and intolerance to non-steroidal anti-inflammatory drugs (including a history);
• thrombocytopenia;
• bleeding diathesis or bleeding disorders, including conditions after surgical interventions associated with the likelihood of bleeding or insufficient hemostasis;
• the period after undergoing coronary artery bypass surgery ;
• changes in the mucous membranes of the duodenum or stomach of the erosive-ulcerative type, active bleeding from the gastrointestinal tract, as well as cerebrovascular or other bleeding;
• previous bleeding from the digestive organs associated with taking non-steroidal anti-inflammatory drugs;
• recurrent stomach ulcers or repeated bleeding from the digestive system;
• exacerbation of inflammatory bowel disease ( Crohn's disease );
• decompensated heart failure;
• liver failure or active liver disease;
• severe renal failure , progressive kidney disease, hyperkalemia , dehydration or hypovolemia ;
• pregnancy and lactation;
• age less than 18 years;
• allergy to the components of the drug.

Caution should be exercised in prescribing the medicine in the presence of at least one of the following conditions: lesions of the digestive tract of an erosive-ulcerative nature and bleeding of the specified localization, moderate renal failure, conditions after surgery, arterial hypertension , age over 65 years, coronary heart disease , cerebrovascular diseases , chronic cardiac failure, dyslipidemia , peripheral arterial disease, diabetes mellitus , smoking, creatinine clearance up to 60 ml/min, the presence of Helicobacter pylori, ulcerative lesions of the digestive tract in the past, long-term use of anti-inflammatory non-steroidal drugs, severe somatic diseases, alcoholism , joint taking oral forms of glucocorticosteroids, anticoagulants, antiplatelet agents, diuretics, selective serotonin uptake blockers or drugs with nephrotoxic effects.

Concomitant therapy with anti-inflammatory nonsteroidal drugs and Tacrolimus may increase the risk of nephrotoxicity.

The simultaneous use of anti-inflammatory non-steroidal drugs and Heparin against the background of epidural or spinal anesthesia increases the likelihood of epidural and spinal hematomas .

To whom is Xefocam contraindicated?

It is necessary to stop using an analgesic:

• with bronchial asthma complicated by polyposis;
• for erosive and ulcerative lesions of the mucous membranes of the stomach and intestines;
• internal bleeding, suspicion of its presence;
• decreased blood clotting, impaired hematopoietic functions;
• Crohn's disease;
• in the period after heart surgery;
• in case of severe liver dysfunction: cirrhosis, acute hepatosis, hepatitis;
• in case of individual intolerance or allergic reactions to the drug.

Contraindications also include: all stages of pregnancy, children under 18 years of age.

Side effects

The most common adverse reactions to taking non-steroidal anti-inflammatory drugs are: the appearance of peptic ulcers , perforation of a hollow organ or bleeding of the gastrointestinal localization. Also noted are abdominal pain, vomiting, nausea, diarrhea, constipation, flatulence , dyspepsia , hematemesis , melena , exacerbation of colitis , ulcerative stomatitis , exacerbation of Crohn's disease , gastritis . Approximately 20% of patients taking this medication may develop adverse reactions.

• reactions from hematopoiesis: anemia , leukopenia , thrombocytopenia , increased duration of bleeding, ecchymosis ;
• reactions from the immune system: allergies;
• metabolic reactions: anorexia , weight gain or loss;
• mental reactions: depression , sleep disturbance, nervousness, confusion, anxious agitation;
• reactions from nervous activity: temporary mild headaches, dizziness, paresthesia , somnolence , tremor , taste disturbance, migraine ;
• reactions from vision: conjunctivitis , blurred vision;
• reactions from the vestibular apparatus: tinnitus, dizziness ;
• reactions from the circulation: tachycardia , palpitations, heart failure , edema, hot flashes , hemorrhages, arterial hypertension , hematoma ;
• reactions from the respiratory organs: rhinitis , dyspnea , pharyngitis , bronchospasm , cough;
• digestive reactions: abdominal pain, nausea, dyspepsia , vomiting , , flatulence , constipation, dry mouth, belching, peptic ulcer , gastritis , ulcerations in the oral mucosa, hematemesis, glossitis , melena , stomatitis , gastroesophageal reflux , esophagitis , aphthous stomatitis , dysphagia , perforated ulcer ;
• reactions from the hepatobiliary system: increased concentrations of glutamate-pyruvate transaminase and glutamate-oxaloacetate transaminase, damage to hepatocytes, impaired liver function;
• skin reactions: itching, rash, sweating, urticaria , dermatitis , alopecia , purpura , bullous reactions, edema, epidermal toxic necrolysis , Stevens-Johnson syndrome ;
• reactions from the musculoskeletal system: arthralgia , muscle spasms, bone pain, myalgia ;
• reactions from the urinary system: urinary disorders, nocturia , increased concentration of urea or creatinine in the blood;
• general reactions: facial swelling , malaise, asthenia .

Side effects of the drug

Occasionally, while using Xefocam, nausea, dry mouth, decreased appetite, abdominal cramps, and swelling occur. In isolated cases, it is also possible:

• physical weakness, drowsiness;
• weight loss;
• increased irritability;
• the appearance of stomatitis;
• exacerbation of gastritis.

Overdose increases the risk of internal bleeding and perforation of a stomach ulcer.

Instructions for use of Xefocam (Method and dosage)

Xefocam tablets, instructions for use

The medicine is taken orally before meals with 100 ml of water.

For moderate to severe pain, the drug is taken in a dose of 8-16 mg per day, divided into 2-3 doses. The maximum daily dose is 16 mg.

For rheumatic diseases of an inflammatory-degenerative nature, 12 mg is recommended as the initial dose. The usual daily dose is 8-16 mg.

The exact dose selection is carried out by the doctor based on the patient’s condition, and the duration of treatment depends on the clinic and the course of the disease.

For damage to the digestive organs, for persons with impaired kidney or liver function, for elderly patients or after major operations, the maximum daily dose is set at 12 mg of the drug per day, divided into 3 doses.

To reduce the likelihood of adverse events, the minimum effective dose should be prescribed for the shortest course.

Xefocam injections, instructions for use

Injections are used only parenterally.

When treating pain after surgery, Xefocam injections are given intravenously or intramuscularly, when treating acute lumbago or ischalgia - only intramuscularly.

The initial injection dose may be 8 or 16 mg. If the analgesic effect is weak after administration of 8 mg of the drug, it is allowed to additionally administer another identical dose.

Injections of medication used as maintenance therapy are prescribed at a dose of 8 mg twice a day. The maximum daily dosage is 16 mg.

Injections should be administered at the minimum effective dose in the shortest possible course.

A solution for parenteral administration is prepared before use by dissolving the contents of the bottle with 2 ml of water for injection. The needle is then replaced. Intramuscular injections are made only with a long needle. The drug solution prepared in the described manner is administered intramuscularly or intravenously. The duration of the injection with the intravenous method should be more than 15 seconds, with the intramuscular method - more than 5 seconds.

Overdose

In case of an overdose of the drug, the following symptoms are possible: dizziness, nausea and vomiting, ataxia , visual disturbances, convulsions , coma . Changes in the liver and kidneys, as well as blood clotting disorders, are possible.

Treatment of overdose: Stop administering or taking the medication. Lornoxicam is quickly evacuated from the body. Dialysis is ineffective. A selective antidote is not known. In case of poisoning with tablets, emergency measures must be taken, including taking enterosorbents and gastric lavage. Ranitidine or prostaglandin are allowed to be used for the treatment of digestive disorders .

Interaction

When used together with Cimetidine, the concentration of lornoxicam in the blood increases.

When used simultaneously with anticoagulants or platelet aggregation blockers, it is possible that the duration of bleeding may increase and the likelihood of bleeding may increase.

Combined use with Phenprocoumon reduces its therapeutic effectiveness.

When taking anti-inflammatory nonsteroidal drugs along with Heparin during spinal or epidural anesthesia, the risk of spinal and epidural hematomas increases.

When used together with ACE blockers and beta-blockers, their hypotensive effect is reduced.

The drug weakens the hypotensive and diuretic effect of diuretics, and also reduces the clearance of Digoxin .

When used together with other anti-inflammatory non-steroidal drugs or glucocorticosteroids, the risk of bleeding from the digestive organs increases.

When used together with quinoline antibiotics, the risk of seizure syndrome increases.

The drug increases the level of methotrexate in the blood when used together.

When used simultaneously with selective serotonin uptake blockers, the risk of bleeding from the digestive organs increases.

Xefocam can cause an increase in the concentration of lithium in the blood, increasing the side effects of the latter when taken together.

Xefocam stimulates the nephrotoxic effects of Cyclosporine and the hypoglycemic effect of sulfonylurea drugs.

When taken together with potassium supplements, corticotropin , alcohol, the risk of undesirable effects on the digestive system increases.

When used simultaneously with Cefotetan , Cefoperazone , Cefamandole , and valproic acid, the likelihood of bleeding increases.

When taken together with Tacrolimus , the risk of nephrotoxicity increases.

Compatibility of the drug with alcohol and other medications

During the period of use of the medication, alcohol should be avoided, since ethanol greatly enhances its toxic effect. Caution is necessary when using Xefocam simultaneously with Cimetidine, Heparin, Methotrexate, Corticotropin, diuretics, antihypertensive drugs from the group of beta blockers and ACE inhibitors. As a result of their combination, a mutual increase in toxicity is likely.

Xefocam is not recommended to be combined with other non-steroidal analgesics, since all of them are characterized by an anticoagulant effect - a decrease in blood clotting.

During the treatment period, you should also refrain from driving a car or operating complex equipment. Xefocam affects the speed of motor skills and mental reactions, which increases the risk of accidents.

special instructions

The likelihood of an ulcerogenic effect of the drug can be reduced by simultaneous use of proton pump inhibitors and artificial prostaglandin analogues. If bleeding from the digestive organs occurs, the medication must be stopped immediately and emergency measures must be taken. It is especially necessary to carefully monitor patients with pathologies of the gastrointestinal tract who are taking the drug for the first time.

Like any other oxicams, the described drug inhibits platelet aggregation, which causes an increase in the duration of bleeding. When using the drug, the condition of patients who require normal physiological functioning of the coagulation system (including those who are planning to undergo surgery), who have blood clotting disorders, or who are taking medications that suppress coagulation, should be carefully monitored in order to promptly identify signs of bleeding .

If signs of liver damage are detected (yellowness of the skin, itching, vomiting, nausea, dark urine, abdominal pain, increased levels of liver transaminases), you should immediately stop using the medication and consult a doctor.

It is prohibited to use the medicine simultaneously with other anti-inflammatory non-steroidal drugs.

Xefocam is able to change the properties of platelets, but it does not replace the preventive effect of Aspirin for cardiovascular disorders.

For patients with impaired renal function caused by severe blood loss or dehydration, the drug, as an inhibitor of prostaglandin biosynthesis, is allowed to be prescribed only after relief of hypovolemia and the resulting risk of decreased renal perfusion.

The described medicine can cause an increase in urea and creatinine in the blood, as well as sodium and water retention, arterial hypertension , peripheral edema and some other initial symptoms of nephropathy . Long-term therapy of such patients with Xefocam can cause glomerulonephritis , nephrotic syndrome and even acute kidney failure.

In elderly people, as well as those suffering from arterial hypertension or obesity , blood pressure should be monitored.

It is especially important to monitor renal function in elderly patients, as well as in persons concomitantly taking diuretics or drugs that potentially cause damage to kidney tissue.

With long-term use of the drug, it is necessary to regularly monitor hematological parameters, as well as kidney and liver parameters.

Persons receiving the drug are strongly advised to refrain from driving and drinking alcohol.

Xefocam 8 mg 10 pcs. film-coated tablets

pharmachologic effect

Non-steroidal anti-inflammatory drug.

Composition and release form Xefocam 8 mg 10 pcs. film-coated tablets

Tablets - 1 tablet:

• Active substance: lornoxicam - 8 mg;
• Excipients: magnesium stearate 2.0 mg, povidone (K25) 5.0 mg, croscarmellose sodium 10.0 mg, cellulose 85.0 mg, lactose monohydrate 90.0 mg;
• Shell: macrogol /60001 0.8 mg, titanium dioxide E-171 1.6 mg, talc 3.2 mg, hypromellose 5.6 mg.

10 tablets in a blister made of aluminum foil and PVC film. 1, 2, 3, 5 or 10 blisters with instructions for use are placed in a cardboard box.

Description of the dosage form

From white to white with a yellowish tint, oblong film-coated tablets with the inscription “LO8” indentation.

Directions for use and doses

For oral administration: for severe pain, recommended dose

8-16 mg/day, divided into 2-3 doses. The maximum daily dose is 16 mg.

For inflammatory and degenerative rheumatic diseases, the recommended starting dose is 12 mg. The standard dose is 8-16 mg per day, depending on the patient's condition.

The duration of therapy depends on the nature and course of the disease.

XEFOCAM tablets are taken orally before meals with a glass of water.

For diseases of the gastrointestinal tract, patients with impaired renal or liver function, elderly people (over 65 years), after major operations - the maximum daily dose is 12 mg, in 3 doses.

To reduce the risk of developing adverse events from the gastrointestinal tract, the minimum effective dose should be used for the shortest possible short course.

Pharmacodynamics

It has a pronounced analgesic and anti-inflammatory effect. Lornoxicam has a complex mechanism of action, which is based on the suppression of PG synthesis due to inhibition of COX activity. In addition, lornoxicam inhibits the release of oxygen free radicals from activated leukocytes. The drug does not have an opiate-like effect on the central nervous system and, unlike narcotic analgesics, does not depress respiration and does not cause drug dependence.

Pharmacokinetics

Lornoxicam is quickly and almost completely absorbed from the gastrointestinal tract after oral administration. In this case, Cmax in plasma is achieved after 1-2 hours, with intramuscular administration - after approximately 0.4 hours. The absolute bioavailability of lornoxicam is 90-100% after oral administration and 97% after intramuscular administration.

Lornoxicam is present in plasma mainly unchanged and, to a lesser extent, in the form of a hydroxylated metabolite, which has no pharmacological activity. The binding of lornoxicam to plasma proteins (mainly the albumin fraction) is 99% and does not depend on its concentration. T1/2, on average, is 4 hours (tablets) and 3-4 hours (lyophilisate) and does not depend on the concentration of the drug.

Completely metabolized. Approximately 1/3 of the metabolites are excreted from the body by the kidneys and 2/3 by the liver. In elderly people, as well as in patients with renal or hepatic insufficiency, no significant changes in the pharmacokinetics of lornoxicam were found.

Indications for use Xefocam 8 mg 10 pcs. film-coated tablets

Short-term treatment of pain of various origins. Symptomatic treatment of rheumatic diseases (rheumatoid arthritis, osteoarthritis, ankylosing spondylitis, articular syndrome with exacerbation of gout, rheumatic soft tissue damage).

Contraindications

• Known hypersensitivity/allergy to lornoxicam or to one of the components of the drug;
• complete or incomplete combination of bronchial asthma, recurrent nasal polyposis or paranasal sinuses and intolerance to acetylsalicylic acid and other NSAIDs (including a history);
• hemorrhagic diathesis or bleeding disorders, as well as those who have undergone operations associated with the risk of bleeding or incomplete hemostasis;
• period after coronary artery bypass surgery;
• erosive and ulcerative changes in the mucous membrane of the stomach or duodenum, active gastrointestinal bleeding;
• cerebrovascular or other bleeding;
• recurrent stomach ulcer or repeated gastrointestinal bleeding;
• Gastrointestinal bleeding associated with a history of taking NSAIDs;
• inflammatory bowel diseases (Crohn's disease, ulcerative colitis) in the acute phase;
• uncompensated heart failure;
• severe liver failure or active liver disease;
• severe renal failure (serum creatinine level more than 300 µmol/l), progressive kidney disease, confirmed hyperkalemia, hypovolemia or dehydration;
• pregnancy, breastfeeding period;
• children under 18 years of age, due to the lack of clinical data on its use in this age group.

With caution: erosive and ulcerative lesions and bleeding from the gastrointestinal tract (history), moderate renal failure, conditions after surgery, age over 65 years, coronary heart disease (CHD), chronic heart failure (CHF), cerebrovascular diseases, dyslipidemia/ hyperlipidemia, diabetes mellitus, peripheral arterial disease, smoking, creatinine clearance (CC) less than 60 ml/min, history of gastrointestinal ulcers, Helicobacter pylori infection, long-term use of NSAIDs, alcoholism, severe somatic diseases, simultaneous use of oral glucocorticosteroids (GCS) (including prednisolone), anticoagulants (including warfarin), antiplatelet agents (including clopidogrel), selective serotonin reuptake inhibitors (including citalopram, fluoxetine, paroxetine, sertraline).

Application of Xefocam 8 mg 10 pcs. film-coated tablets during pregnancy and breastfeeding

Contraindicated for children under 14 years of age, during pregnancy and breastfeeding.

special instructions

The risk of ulcerogenic effects of the drug can be reduced by the simultaneous administration of proton pump inhibitors and synthetic prostaglandin analogues. If bleeding occurs in the gastrointestinal tract, the drug should be stopped immediately and appropriate emergency measures taken. It is especially necessary to carefully monitor the condition of those patients with gastrointestinal pathology who are receiving a course of treatment with XEFOCAM for the first time.

Like other oxicams, XEFOCAM inhibits platelet aggregation and may therefore increase bleeding time. When using this drug, patients who require completely normal coagulation function (for example, patients undergoing surgery), who have coagulation disorders, or who are receiving medications that inhibit coagulation (including low-dose heparin) should be closely monitored when using this drug. , in order to promptly detect signs of bleeding.

If signs of liver damage appear (itching, yellowing of the skin, nausea, vomiting, abdominal pain, dark urine, increased levels of liver transaminases), you should stop taking the drug and consult your doctor.

The drug should not be used simultaneously with other NSAIDs.

The drug can change the properties of platelets, but does not replace the preventive effect of acetylsalicylic acid in cardiovascular diseases.

In patients with impaired renal function caused by large blood loss or severe dehydration, XEFOCAM, as an inhibitor of prostaglandin synthesis, can be prescribed only after hypovolemia and the associated risk of decreased renal perfusion have been eliminated. Like other NSAIDs, XEFOCAM can cause an increase in blood urea and creatinine concentrations, as well as water and sodium retention, peripheral edema, hypertension and other early signs of nephropathy. Long-term treatment of such patients with XEFOCAM can lead to the following consequences: glomerulonephritis, papillary necrosis and nephrotic syndrome with transition to acute renal failure. Patients with a marked decrease in renal function should not be prescribed XEFOCAM. In elderly patients, as well as in patients suffering from arterial hypertension and/or obesity, it is necessary to control blood pressure levels.

It is especially important to monitor renal function in elderly patients, as well as in patients:

• simultaneously receiving diuretics;
• concurrently receiving medications that may cause kidney damage.

With long-term use of the drug XEFOCAM, it is necessary to periodically monitor hematological parameters, as well as renal and liver function.

Impact on the ability to drive vehicles and operate machinery

Patients using the drug must refrain from activities that require increased attention, rapid mental and motor reactions, and alcohol consumption.

Overdose

Symptoms: the side effects of XEFOCAM described above may increase. Treatment: symptomatic.

Taking activated carbon immediately after taking XEFOCAM may help reduce the absorption of this drug. Antiulcer drugs can be used to prevent damage to the mucous membrane.

Dialysis is ineffective.

Side effects of Xefocam 8 mg 10 pcs. film-coated tablets

From the gastrointestinal tract and liver: dyspepsia, abdominal pain, dry mouth, stomatitis, nausea, vomiting, heartburn, diarrhea; esophagitis, gastritis, erosive and ulcerative lesions of the mucous membrane of the stomach and intestines, incl. with perforation and bleeding, constipation, flatulence, melena, liver dysfunction, increased levels of liver transaminases.

From the nervous system: headache, dizziness, drowsiness, sleep disturbances, depression, agitation, tremor, aseptic meningitis, paresthesia.

From the skin and subcutaneous fat: edematous syndrome, ecchymosis, skin rash, itching, urticaria, alopecia, Stevens-Johnson syndrome, Lyell's syndrome, angioedema.

From the urinary system: dysuria, decreased glomerular filtration, interstitial nephritis, glomerulonephritis, papillary necrosis, nephrotic syndrome, peripheral edema, acute renal failure.

From the senses: tinnitus, blurred vision.

From the cardiovascular system: development or worsening of heart failure, tachycardia, increased blood pressure (BP).

From the hematopoietic organs and hemostasis system: agranulocytosis, leukopenia, anemia, thrombocytopenia, increased bleeding time.

From the respiratory system: pharyngitis, rhinitis, dyspnea, cough, bronchospasm.

Other: anorexia, increased sweating, changes in body weight, arthralgia and myalgia.

Drug interactions

Simultaneous use of the drug XEFOCAM and:

• cimetidine - increases the concentration of lornoxicam in plasma. No interactions with ranitidine and antacid drugs have been identified;
• anticoagulants or platelet aggregation inhibitors - possible increase in bleeding time (increased risk of bleeding, international normalized ratio (INR) monitoring is required);
• beta-blockers and angiotensin-converting enzyme inhibitors may reduce their hypotensive effect;
• diuretics - reduces the diuretic effect and hypotensive effect;
• digoxin - reduces the renal clearance of digoxin;
• quinolone antibiotics - increases the risk of developing seizures;
• other NSAIDs or glucocorticoids - increases the risk of gastrointestinal bleeding;
• methotrexate - increases the concentration of methotrexate in the serum;
• selective serotonin reuptake inhibitors (for example, citalopram, fluoxetine, paroxetine, sertraline) increases the risk of gastrointestinal bleeding;
• lithium salts - may cause an increase in peak plasma lithium concentrations and thereby increase the known side effects of lithium;
• cyclosporine - increases the nephrotoxicity of cyclosporine;
• sulfonylurea derivatives - may enhance the hypoglycemic effect of the latter;
• alcohol, corticotropin, potassium supplements increases the risk of side effects from the gastrointestinal tract;
• cefamandole, cefoperazone, cefotetan, valproic acid increases the risk of bleeding.

Analogues of Xefocam

Level 4 ATX code matches:
Mirlox

Revmoxicam

Xefocam Rapid

Movalis

Mesipol

Lem

Melbek

Movasin

Piroxicam

Lornoxicam

Arthrozan

Texamen

Amelotex

Meloxicam

• Zornica
• Xefocam Rapid
• Larfix
• Lorakam
• Aroxicam
• Aspikam
• Loxidol
• Melbek
• Meloxicam
• Revmalim
• Rekoksa

The price of Xefocam analogues, which are listed above, is in almost all cases higher than the price of Xefokam itself.

Xefocam price, where to buy

The price of Xefocam in tablets of 8 mg No. 10 in Russia is about 250 rubles. For comparison, the price of 5 ampoules with lyophilisate is approximately 800 rubles.

Buying Xefocam 8 mg No. 10 in Ukraine will cost an average of 100 hryvnia, and the price of Xefocam No. 5 injections reaches 450 hryvnia.

• Online pharmacies in RussiaRussia
• Online pharmacies in UkraineUkraine
• Online pharmacies in KazakhstanKazakhstan

ZdravCity

• Xefocam tablets p.p.o.
  8 mg 30 pcs. Takeda GmbH RUB 538 order
• Xefocam tablets p.p.o. 8 mg 10 pcs. Takeda GmbH

  RUB 263 order

• Xefocam liof. d/prig. solution for intravenous and intramuscular injection. 8mg vial. No.5Wasserburger Arzneumittelwerk GmbH

  RUR 783 order

Pharmacy Dialogue

• Xefocam (vial 8 mg No. 5)Wasserburger

  770 rub. order

• Xefocam (tablet p/o 8 mg No. 10)Takeda

  RUB 235 order

• Xefocam (tab.p.pl/vol.8mg No. 30)Takeda

  516 RUR order

show more

Pharmacy24

• Xefocam 8 mg No. 10 tablets Nycomed Austria GmbH.Austria/Nycomed Austria GmbH.Austria,Nimechchina/Takeda GmbH, Nimechchina
  94 UAH.order
• Xefocam 4 mg N10 tablets Takeda GmbH, city of Vir-va Oranienburg, Germany

  59 UAH order

• Xefocam 8 mg No. 5 lyophilisate Nycomed Austria GmbH.Austria/Takeda Austria GmbH,Austria

  446 UAH. order

PaniPharmacy

• Xefocam tablets Xefokam tablets. p/o 8 mg No. 10 Germany, Takeda

  110 UAH order

• Ksefokam bottle Ksefokam por. d/in. 8ml fl. No.5 Austria, Takeda Austria

  481 UAH order

• Xefocam tablets Xefokam tablets. p/o 4 mg No. 10 Germany, Takeda

  75 UAH order

show more